Laura Pérez-Ortega - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Frontiers in Immunology|January 5, 2026

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemiaPatricia Alcalde-Mellado, Victoria Ruiz-Maldonado, Javier Delgado-Serrano, et al.

Cellular Oncology (Dordrecht, Netherlands)|August 27, 2024

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell featuresBelén Sierro-Martínez, Virginia Escamilla-Gómez, Laura Pérez-Ortega, et al.

Bone Marrow Transplantation|March 15, 2023

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART eraAlberto Mussetti, Leyre Bento, Mariana Bastos-Oreiro, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Frontiers in Immunology|January 5, 2026

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemiaPatricia Alcalde-Mellado, Victoria Ruiz-Maldonado, Javier Delgado-Serrano, et al.

Cellular Oncology (Dordrecht, Netherlands)|August 27, 2024

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell featuresBelén Sierro-Martínez, Virginia Escamilla-Gómez, Laura Pérez-Ortega, et al.

Bone Marrow Transplantation|March 15, 2023

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART eraAlberto Mussetti, Leyre Bento, Mariana Bastos-Oreiro, et al.

Pageof 1